Sandra P. D’Angelo, MD, discusses data from substudy 2 of the phase 2 IGNYTE-ESO trial evaluating lete-cel in SyS and MRCLS.
Sandra P. D'Angelo, MD
Advertisement
Articles by Sandra P. D'Angelo, MD
Sandra P. D’Angelo, MD, discusses the incidence and prognosis of patients with Merkel cell carcinoma.
Sandra P. D’Angelo, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the results of a pilot study investigating the combination of bempegaldesleukin (NKTR-214) plus nivolumab (Opdivo) in patients with sarcomas.
Advertisement
Latest Updated Articles
Dr. D’Angelo on the Incidence and Prognosis of Merkel Cell CarcinomaPublished: May 25th 2021 | Updated:
Dr. D'Angelo on Bempegaldesleukin/Nivolumab Combo in SarcomasPublished: September 3rd 2019 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
4
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
5